LOGIN  |  REGISTER
C4 Therapeutics

Syra Health to Participate in Lytham Partners 2024 Investor Select Conference

January 16, 2024 | Last Trade: US$0.94 0.06 -5.86

CARMEL, Ind., Jan. 16, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it will be participating in Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024.

1x1 Meetings

Syra Health Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it. or register at https://lythampartners.com/select2024invreg/

Further information on the conference is available at https://lythampartners.com/select2024.

ABOUT SYRA HEALTH CORP.

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.

For more information, please contact:

For Media Inquiries:

Christine Drury

Communications and Marketing Director

Syra Health Corp.

463-345-5180

This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investor Inquiries:

Ben Shamsian

Vice President

Lytham Partners, LLC

646-829-9701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB